Form 4: Becton Dickinson Executive Sells Shares Under 10b5-1 Plan

Michael David Garrison, EVP & President of Medical at Becton Dickinson, sold 2,838 shares of common stock at $223.33 per share on December 19, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Michael David Garrison, an Executive Vice President and President of Medical at Becton Dickinson & Co, sold 2,838 shares of the company's common stock on December 19, 2024.
• The sale was executed at a price of $223.33 per share.
• This transaction was conducted under a pre-established Rule 10b5-1 trading plan.
• Following the transaction, Mr. Garrison directly owns 6,141 shares of Becton Dickinson stock.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by an executive under a pre-arranged plan, which is neither positive nor negative for the company's performance.

Industry Context

Executive stock sales are a common occurrence and are often part of pre-planned strategies for personal financial management. The use of a 10b5-1 plan indicates that the sale was not based on any non-public information.

Comparison to Industry Standards

• Executive stock sales are a normal part of compensation and financial planning across the industry.
• The use of a 10b5-1 plan is a common practice among executives at publicly traded companies, including competitors such as Medtronic (MDT) and Abbott Laboratories (ABT), to avoid accusations of insider trading.
• The volume of shares sold is relatively small compared to the total outstanding shares of Becton Dickinson, and is not unusual for an executive sale.

Stakeholder Impact

• The stock sale is unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

Becton Dickinson, BDX, insider trading, stock sale, Rule 10b5-1, executive, Michael David Garrison